Ambera Dedic, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Overlake Hospital Medical Center & Clinics · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Ambera Dedic’s office at (650) 723-4000 to ask if they take your plan before you enroll.
State licence records
1 licence
- Washington ARNP.AP.61173424-NPAdvanced Registered Nurse Practitioner License · since 2021 · expires 2026-04-22ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Overlake Hospital Medical Center & ClinicsBellevue, WAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Overlake Medical Center and ClinicsPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Abdominal Hysterectomy: 2.969, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.33, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Overlake Hospital Medical Center & Clinics
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Abdominal HysterectomyInfections | 2.969 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.33 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.43 (0.49 to 2.37) · 1,094 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.68 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 219.06 (166.89 to 271.22) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 59 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 14.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.2 · 123 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.6 · 417 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.2 · 375 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 3,665 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 5,678 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.09 to 0.48) · 5,701 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,767 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.25 (0.78 to 3.73) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.25 to 4.07) · 1,703 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.06 (5.24 to 16.87) · 850 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.41 (1.01 to 7.81) · 830 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.27 (0.8 to 3.75) · 355 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0 to 1.09) · 4,643 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 60 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.582 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.7 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.91 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.4 · 221 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 700 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 50.4 · 136 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 450 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.3 · 347 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 578 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.1 to 8.1) · 32 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (6.5 to 14.7) · 32 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 63 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 77 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 90 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.7) · 189 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 937 cases | No different | Jan 2024 – Dec 2024 |
What patients said (788 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$62,717
Medicare paid this office $62,717 for 225 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 213 | $35,371 | $88 |
| Injection, denosumab, 1 mg | 14 | $21,916 | None |
| Hemoglobin a1c level | 90 | $1,266 | $10 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $702 | $23 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 54 | $644 | $12 |
See all 7 services
| Return visit (30+ min) | 213 | $35,371 | $88 |
| Injection, denosumab, 1 mg | 14 | $21,916 | None |
| Hemoglobin a1c level | 90 | $1,266 | $10 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $702 | $23 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 54 | $644 | $12 |
| Injection of drug or substance under skin or into muscle | 12 | $165 | $11 |
| Insertion of needle into vein for collection of blood sample | 13 | $122 | $7 |
Who their Medicare patients are
225 Original Medicare patients in 2024. Average age 77 · Women 53% · Also on Medicaid 8% · Health risk score 1.58. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 54% · Coronary heart disease 44% · Heart failure 24% · Depression 24% · Atrial fibrillation 23% · COPD 18% · Cancer 17% · Dementia 12% · Stroke 6%.
The office billed $204,919, Medicare allowed $82,099 and paid $62,717; for 1,758 services of 12 kinds; $21,916 of it was for drugs given in the office and $40,801 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 225 | 1,758 | 77 | 1.58 | $204,919 | $62,717 |
| 2023 | 220 | 2,636 | 77 | 1.49 | $219,973 | $66,327 |
| 2022 | 193 | 1,448 | 77 | 1.40 | $162,432 | $49,634 |
| 2021 | 49 | 161 | 76 | 1.36 | $24,171 | $8,337 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 200 | $33,582 | $84 |
| Injection, denosumab, 1 mg | 14 | $18,984 | None |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 89 | $3,867 | $23 |
| Hemoglobin a1c level | 107 | $1,395 | $9 |
| Short return visit (20+ min) | 18 | $1,041 | $55 |
| Injection of drug or substance under skin or into muscle | 13 | $172 | $11 |
| Insertion of needle into vein for collection of blood sample | 11 | $57 | $4 |
2022: 6 services
| Return visit (30+ min) | 178 | $28,740 | $87 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 70 | $3,022 | $25 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 19 | $2,468 | $130 |
| Hemoglobin a1c level | 78 | $1,015 | $10 |
| Short return visit (20+ min) | 11 | $732 | $67 |
| Insertion of needle into vein for collection of blood sample | 15 | $59 | $3 |
2021: 3 services
| Return visit (30+ min) | 40 | $4,850 | $95 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 13 | $414 | $26 |
| Hemoglobin a1c level | 17 | $165 | $10 |
Medicaid work
$5,568 in 2024
Medicaid paid $5,568 for 144 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 144 | $5,568 |
| 2024 | 144 | 1 | 24 | $5,568 |
| 2023 | 143 | 1 | 21 | $4,179 |
| 2022 | 83 | 1 | 21 | $2,414 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 143 | $4,179 |
2022
| Return visit (30+ min) | 83 | $2,414 |
Drugs they prescribed that Part D paid
$1,909,025
Pharmacies billed $1,909,025 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,724) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,512 generic and 1,846 brand-name prescriptions · $1,909,025 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 270 | $469,040 | $1,737 |
| Mounjaro | 149 | $227,022 | $1,524 |
| Trulicity | 109 | $167,789 | $1,539 |
| Jardiance | 110 | $139,355 | $1,267 |
| Tresiba Flextouch U-200 | 91 | $113,212 | $1,244 |
See all 54 drugs
| Ozempic | 270 | $469,040 | $1,737 |
| Mounjaro | 149 | $227,022 | $1,524 |
| Trulicity | 109 | $167,789 | $1,539 |
| Jardiance | 110 | $139,355 | $1,267 |
| Tresiba Flextouch U-200 | 91 | $113,212 | $1,244 |
| Synjardy Xr | 56 | $81,361 | $1,453 |
| Farxiga | 55 | $72,878 | $1,325 |
| Xultophy 100-3.6 | 45 | $71,495 | $1,589 |
| Soliqua 100-33 | 61 | $61,945 | $1,015 |
| Tresiba Flextouch U-100 | 93 | $52,424 | $564 |
| Afrezza | 22 | $48,423 | $2,201 |
| Rybelsus | 15 | $42,301 | $2,820 |
| Novolog Flexpen | 105 | $29,113 | $277 |
| Basaglar Kwikpen U-100 | 45 | $28,152 | $626 |
| Januvia | 18 | $28,079 | $1,560 |
| Lantus Solostar | 171 | $24,773 | $145 |
| Humalog Kwikpen U-100 | 65 | $23,414 | $360 |
| Fiasp Flextouch | 22 | $20,506 | $932 |
| Xigduo Xr | 12 | $20,240 | $1,687 |
| Victoza 3-Pak | 11 | $17,557 | $1,596 |
| Nano 2nd Gen Pen Needle | 98 | $10,967 | $112 |
| Insulin Lispro Kwikpen U-100 | 30 | $8,139 | $271 |
| Toujeo Solostar | 16 | $7,931 | $496 |
| Droplet Pen Needle | 54 | $5,217 | $97 |
| Metformin Hcl Er | 282 | $4,175 | $15 |
| Ultra-Fine Short Pen Needle | 30 | $4,058 | $135 |
| Ultra-Fine Nano Pen Needle | 19 | $2,547 | $134 |
| Levothyroxine | 234 | $2,528 | $11 |
| Synthroid | 52 | $2,405 | $46 |
| Rosuvastatin | 94 | $1,859 | $20 |
| Metformin | 196 | $1,787 | $9 |
| Humulin N | 15 | $1,573 | $105 |
| Ultra-Fine Mini Pen Needle | 19 | $1,473 | $78 |
| Ultra-Fine Micro Pen Needle | 12 | $1,445 | $120 |
| Atorvastatin | 78 | $1,050 | $13 |
| Repaglinide | 32 | $997 | $31 |
| Glipizide | 43 | $943 | $22 |
| Gabapentin | 54 | $932 | $17 |
| Liothyronine | 19 | $783 | $41 |
| Ezetimibe | 27 | $766 | $28 |
| Glipizide Er | 59 | $716 | $12 |
| Trueplus Pen Needle | 11 | $698 | $63 |
| Glimepiride | 90 | $625 | $7 |
| Methimazole | 52 | $503 | $10 |
| Lisinopril | 38 | $384 | $10 |
| Losartan | 29 | $285 | $10 |
| Amlodipine Besylate | 31 | $229 | $7 |
| Ondansetron Odt | 12 | $200 | $17 |
| Pioglitazone | 27 | $196 | $7 |
| Alcohol Prep Pads | 30 | $147 | $5 |
| Hydrochlorothiazide | 13 | $116 | $9 |
| Alendronate | 15 | $106 | $7 |
| Simvastatin | 11 | $87 | $8 |
| Dropsafe Prep Pads | 15 | $76 | $5 |
Year by year
| 2024 | 3,724 | 398 | 0% (0) | 50% | $1,909,025 |
| 2023 | 2,692 | 338 | 0% (0) | 53% | $1,773,331 |
| 2022 | 1,321 | 251 | 0% (0) | 52% | $781,808 |
| 2021 | 140 | 70 | 0% (0) | 49% | $67,482 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 49 drugs
| Ozempic | 169 | $356,817 | $2,111 |
| Trulicity | 104 | $171,150 | $1,646 |
| Lantus Solostar | 170 | $136,522 | $803 |
| Humalog Kwikpen U-100 | 82 | $106,848 | $1,303 |
| Jardiance | 80 | $105,971 | $1,325 |
| Novolog Flexpen | 86 | $104,506 | $1,215 |
| Mounjaro | 55 | $97,908 | $1,780 |
| Tresiba Flextouch U-200 | 67 | $86,723 | $1,294 |
| Xultophy 100-3.6 | 29 | $65,505 | $2,259 |
| Soliqua 100-33 | 49 | $56,072 | $1,144 |
| Afrezza | 32 | $53,067 | $1,658 |
| Victoza 3-Pak | 21 | $52,826 | $2,516 |
| Farxiga | 35 | $52,243 | $1,493 |
| Synjardy Xr | 30 | $49,978 | $1,666 |
| Tresiba Flextouch U-100 | 74 | $45,338 | $613 |
| Rybelsus | 11 | $22,514 | $2,047 |
| Januvia | 15 | $19,584 | $1,306 |
| Levemir Flexpen | 11 | $14,561 | $1,324 |
| Fiasp Flextouch | 14 | $7,691 | $549 |
| Nano 2nd Gen Pen Needle | 51 | $6,467 | $127 |
| Basaglar Kwikpen U-100 | 13 | $6,204 | $477 |
| Insulin Lispro Kwikpen U-100 | 23 | $6,201 | $270 |
| Toujeo Solostar | 16 | $5,562 | $348 |
| Humulin N | 16 | $5,444 | $340 |
| Metformin Hcl Er | 186 | $4,096 | $22 |
| Droplet Pen Needle | 46 | $3,524 | $77 |
| Synthroid | 35 | $2,741 | $78 |
| Ultra-Fine Short Pen Needle | 18 | $2,630 | $146 |
| Levothyroxine | 168 | $2,098 | $12 |
| Ultra-Fine Nano Pen Needle | 23 | $1,981 | $86 |
| Rosuvastatin | 81 | $1,932 | $24 |
| Metformin | 139 | $1,480 | $11 |
| Autoshield Duo Pen Needle | 13 | $1,226 | $94 |
| Repaglinide | 29 | $1,059 | $37 |
| Atorvastatin | 69 | $810 | $12 |
| Sure Comfort Pen Needle | 19 | $761 | $40 |
| Liothyronine | 15 | $659 | $44 |
| Pen Needle | 14 | $556 | $40 |
| Ezetimibe | 11 | $532 | $48 |
| Glimepiride | 59 | $522 | $9 |
| Pioglitazone | 26 | $460 | $18 |
| Glipizide Er | 20 | $443 | $22 |
| Methimazole | 21 | $327 | $16 |
| Losartan | 32 | $303 | $9 |
| Glipizide | 20 | $237 | $12 |
| Alendronate | 16 | $155 | $10 |
| Lisinopril | 25 | $129 | $5 |
| Amlodipine Besylate | 18 | $82 | $5 |
| Single Use Swab | 14 | $37 | $3 |
2022: 28 drugs
| Ozempic | 90 | $161,248 | $1,792 |
| Trulicity | 56 | $83,530 | $1,492 |
| Lantus Solostar | 99 | $79,750 | $806 |
| Jardiance | 49 | $74,679 | $1,524 |
| Novolog Flexpen | 38 | $60,308 | $1,587 |
| Tresiba Flextouch U-200 | 26 | $45,209 | $1,739 |
| Tresiba Flextouch U-100 | 45 | $34,241 | $761 |
| Humalog Kwikpen U-100 | 34 | $31,087 | $914 |
| Victoza 3-Pak | 15 | $29,423 | $1,962 |
| Farxiga | 35 | $29,100 | $831 |
| Levemir Flextouch | 25 | $11,790 | $472 |
| Insulin Lispro Kwikpen U-100 | 32 | $8,086 | $253 |
| Nano 2nd Gen Pen Needle | 29 | $3,131 | $108 |
| Metformin Hcl Er | 128 | $2,098 | $16 |
| Levothyroxine | 95 | $1,344 | $14 |
| Repaglinide | 49 | $1,339 | $27 |
| Droplet Pen Needle | 13 | $978 | $75 |
| Synthroid | 16 | $945 | $59 |
| Unifine Pentips | 17 | $586 | $34 |
| Methimazole | 20 | $460 | $23 |
| Trueplus Pen Needle | 11 | $356 | $32 |
| Metformin | 57 | $336 | $6 |
| Rosuvastatin | 15 | $287 | $19 |
| Pioglitazone | 21 | $208 | $10 |
| Atorvastatin | 14 | $152 | $11 |
| Glimepiride | 12 | $130 | $11 |
| Glipizide | 22 | $110 | $5 |
| Losartan | 11 | $73 | $7 |
2021: 2 drugs
| Jardiance | 14 | $8,598 | $614 |
| Metformin Hcl Er | 15 | $107 | $7 |
Money from drug and device companies
$2,121 in 2025
| 2025 | 10 | 20 | None | $2,121 |
| 2024 | 8 | 24 | None | $918 |
| 2023 | 6 | 27 | None | $607 |
| 2022 | 10 | 25 | None | $715 |
| 2021 | 3 | 10 | None | $334 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Minimed 780g | $490 | 5 payments
|
| Mannkind | Afrezza | $320 | 5 payments
|
| Novo Nordisk | Wegovy | $233 | 2 payments
|
| Radius Health | Tymlos | $219 | 2 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $176 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $153 | 1 payment
|
See all 20 published payments
| Beta Bionics | Meals · 2025-12-29 | Ilet Bionic Pancreas | $121 |
| Mannkind | Meals · 2025-12-08 | Afrezza | $51 |
| Novo Nordisk | Meals · 2025-11-20 | Wegovy | $122 |
| Medtronic | Meals · 2025-11-18 | Minimed 780g | $147 |
| Lilly USA | Meals · 2025-11-05 | Mounjaro | $115 |
| Insulet | Meals · 2025-10-30 | Omnipod | $149 |
| Dexcom | Meals · 2025-10-23 | Dexcom G6 Transmitter | $153 |
| Mannkind | Meals · 2025-10-22 | Afrezza | $47 |
| Radius Health | Meals · 2025-10-09 | Tymlos | $123 |
| Sequel Med Tech | Meals · 2025-09-15 | Twiist | $145 |
| Medtronic | Meals · 2025-08-28 | Minimed 780g | $106 |
| Novo Nordisk | Meals · 2025-08-20 | Ozempic | $111 |
| Mannkind | Meals · 2025-07-10 | Afrezza | $60 |
| Abbott Laboratories | Meals · 2025-05-13 | Freestyle Libre 3 | $176 |
| Radius Health | Meals · 2025-04-29 | Tymlos | $96 |
| Medtronic | Meals · 2025-04-14 | Minimed 780g | $43 |
| Mannkind | Meals · 2025-03-26 | Afrezza | $145 |
| Medtronic | Meals · 2025-01-30 | Minimed 780g | $169 |
| Mannkind | Meals · 2025-01-09 | Afrezza | $17 |
| Medtronic | Meals · 2025-01-07 | Minimed 780g | $24 |
See earlier years (2024, 2023, 2022, 2021)
2024: $918
| Medtronic | Minimed 780g | $224 | 3 payments
|
| Mannkind | Afrezza | $201 | 7 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $130 | 4 payments
|
| Beta Bionics | Ilet Bionic Pancreas | $125 | 1 payment
|
| Ascensia Diabetes Care Us | Eversense E3 Sensor Kit - Retail | $74 | 4 payments
|
| Dexcom | Dexcom G6 Transmitter | $62 | 1 payment
|
| Novo Nordisk | Ozempic | $58 | 2 payments
|
| Lilly USA | Mounjaro | $45 | 2 payments
|
2023: $607
| MannKind | Afrezza | $209 | 8 payments
|
| Novo Nordisk | Ozempic | $137 | 12 payments
|
| GlaxoSmithKline | Arexvy | $125 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $79 | 3 payments
|
| Lilly USA | Mounjaro | $42 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
2022: $715
| Novo Nordisk | Ozempic | $236 | 8 payments
|
| Horizon Therapeutics plc | Tepezza | $125 | 1 payment
|
| Lilly USA | Mounjaro | $87 | 4 payments
|
| Medtronic | Inpen Smart Insulin Delivery System | $73 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $61 | 3 payments
|
| Mannkind | Afrezza | $52 | 2 payments
|
| Bigfoot Biomedical | Unity Diabetes Management System | $26 | 1 payment
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $21 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $20 | 1 payment
|
| CeQur | Cequr Simplicity | $14 | 1 payment
|
2021: $334
| Novo Nordisk | Ozempic | $186 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $130 | 1 payment
|
| Medtronic | Inpen | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 79.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003498213
- Licence
- WA AP61173424Washington ARNP.AP.61173424-NP: Expired
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2021-04-27
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.